In terms of the impact on healthcare systems, the top four cancers, by estimated new cases, represent 57% of new cases within the top thirteen and 61% of the estimated deaths for this group.
Our Thursday, September 12, 2019, update focused on Breast Cancer
Today we focus on Lung Cancer.
Lung Cancer, with the second most frequent occurrence of new cases, is also the deadliest with a 63% mortality rate. Prescribe Right’s Pharmaceutical Pipeline Tracker shows twenty-one investigational drugs focused on Lung Cancer. Seventeen are in Phase III trials. Several of these efforts are focused on multiple cancers. Ten are focused solely on non-small cell lung cancer, six of which are in Phase III trials.
There are no investigational drugs focused on Lung Cancer within the twenty-four that have PDUFA Dates between November 2, 2019 and August 5, 2020. There are, however, nine drugs to treat Lung Cancer with Priority Designations from the FDA. Seven drugs have Orphan Drug designations and two of the nine are Breakthrough Therapies.
Subscribe to the Pharmaceutical Pipeline Tracker to review investigational drugs focused on Lung Cancer. Read about safety, efficacy and the latest news. Take a look at published research links.
Stay informed, subscribe to the
Prescribe Right Pharmaceutical Pipeline Tracker
Latest Tweets from Prescribe Right